Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health, Inc. is asking stockholders to vote at its June 11, 2026 virtual annual meeting on three items: electing nine directors, ratifying KPMG LLP as auditor for 2026, and approving executive pay on an advisory basis. The Board unanimously recommends voting “FOR” all proposals.
The proxy highlights strong 2025 performance, with revenue of $2.35 billion, up 59% year over year, and more than 2.5 million subscribers, up 13%. Net income was $128.4 million, compared with $126.0 million in 2024, while Adjusted EBITDA reached $318.0 million. Operating cash flow was $300.0 million and Free Cash Flow was $57.4 million.
The company is a NYSE “controlled company” because CEO Andrew Dudum, through Class A and high-vote Class V shares, holds over 50% of voting power and approximately 87.7% of total voting power. Despite this status, a majority of directors are independent, and all audit and compensation committee members are independent. The proxy also describes board committee structures, risk oversight, diversity metrics, and a pay program that is heavily equity-based and performance-linked, with executives earning about 94% of target 2025 bonuses based on revenue and Adjusted EBITDA results.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton sold 9,463 shares of Class A Common Stock in an open-market transaction at $30.00 per share. After the sale, Boughton directly holds 299,368 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
Hims & Hers Health Chief Financial Officer Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock. On April 20, 2026, he exercised options for 7,000 shares at $11.53 and 5,553 shares at $5.01, acquiring a total of 12,553 shares. The same day, he completed an open-market sale of 19,645 shares at an average price of $29.9626, under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following these transactions, he held 262,954 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing notes the options exercised were fully vested, with some awards vesting monthly over four years beginning April 1, 2023.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported option exercises and share sales under a pre-arranged Rule 10b5-1 trading plan. On April 16–17, Okupe sold a total of 54,927 shares of Class A Common Stock in open-market transactions at average prices of $25.8964 and $27.8344. He also exercised stock options for 6,184 shares at an exercise price of $5.01 per share, converting derivative awards into common stock. Following these transactions, Okupe holds 270,046 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust, and retains stock options representing 129,403 shares expiring on February 23, 2032.
HIMS reported proposed sales of Class A common stock under Form 144. The filing lists proposed transfers tied to restricted stock vesting with amounts of 4,651 shares (12/15/2025) and 4,812 shares (03/15/2026). The excerpt also shows prior sales in the past three months: 4,651 shares sold on 02/27/2026 for $70,741.71 and 4,812 shares sold on 03/17/2026 for $118,808.28.
Hims & Hers Health, Inc. Chief Executive Officer Andrew Dudum reported a bona fide gift of a total of 845,866 shares of Class A Common Stock on April 9, 2026. The Form 4 shows two gift transactions of 422,933 shares each, recorded as non-derivative dispositions with no price paid.
After the gifts, Dudum holds 887,684 shares directly. He also has indirect holdings through several trusts, including 470,457 shares held by the Trustee of the Dudum Family Community Property Trust and additional blocks held in various Dudum family and GRAT trusts. These entries reflect estate and trust planning rather than open-market trading activity.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised stock options and sold the resulting shares. He exercised options for 3,975 shares of Class A Common Stock at an exercise price of $5.01 per share, then sold 3,975 shares at an average price of $19.977 per share.
The option exercise and sale were made under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he holds 318,789 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
HIMS reported Form 144 sales by Oluyemi Okupe, who sold multiple blocks of Common Stock on various dates. The filing lists specific sale transactions including 4,490 shares on 02/03/2026 and 3,658 shares on 04/06/2026 with dollar proceeds recorded for each trade.
The Vanguard Group filed Amendment No. 5 to its Schedule 13G/A reporting on Hims & Hers Health Inc. common stock. The amendment states amount beneficially owned: 0 and percent of class: 0%, reflecting an internal realignment described as being made “in accordance with SEC Release No. 34-39538 (January 12, 1998).”
The filing explains certain subsidiaries or business divisions will report beneficial ownership separately after the realignment. The filing is signed by Ashley Grim, Head of Global Fund Administration.